Edwards Lifesciences (EW) Expected to Announce Quarterly Earnings on Thursday

Edwards Lifesciences (NYSE:EW) is projected to announce its Q3 2025 results after the market closes on Thursday, October 30th. Analysts expect Edwards Lifesciences to post earnings of $0.59 per share and revenue of $1.4950 billion for the quarter. Interested persons can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Thursday, October 30, 2025 at 5:00 PM ET.

Edwards Lifesciences Price Performance

EW stock opened at $82.26 on Wednesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. The firm has a market capitalization of $48.29 billion, a P/E ratio of 11.84, a P/E/G ratio of 3.88 and a beta of 1.05. The business’s 50-day moving average is $77.49 and its two-hundred day moving average is $76.65. Edwards Lifesciences has a 1 year low of $64.89 and a 1 year high of $83.25.

Analysts Set New Price Targets

A number of research firms have issued reports on EW. Evercore ISI set a $88.00 price target on Edwards Lifesciences and gave the company an “outperform” rating in a research report on Tuesday, October 7th. Daiwa America raised Edwards Lifesciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 29th. Truist Financial increased their price target on Edwards Lifesciences from $82.00 to $87.00 and gave the company a “hold” rating in a research report on Tuesday. The Goldman Sachs Group reaffirmed a “buy” rating on shares of Edwards Lifesciences in a research report on Friday, July 25th. Finally, BTIG Research raised Edwards Lifesciences from a “neutral” rating to a “buy” rating and set a $100.00 target price on the stock in a research report on Tuesday, July 29th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $87.33.

Insider Buying and Selling

In related news, insider Larry L. Wood sold 8,950 shares of the company’s stock in a transaction on Monday, August 18th. The stock was sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the transaction, the insider directly owned 206,900 shares in the company, valued at approximately $16,150,614. This represents a 4.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 0.34% of the company’s stock.

Institutional Investors Weigh In On Edwards Lifesciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Rakuten Securities Inc. increased its stake in Edwards Lifesciences by 413.7% during the second quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock worth $29,000 after acquiring an additional 302 shares during the last quarter. Chapman Financial Group LLC acquired a new stake in Edwards Lifesciences during the second quarter worth about $63,000. MUFG Securities EMEA plc acquired a new stake in Edwards Lifesciences during the second quarter worth about $136,000. ICONIQ Capital LLC acquired a new stake in Edwards Lifesciences during the second quarter worth about $230,000. Finally, Modern Wealth Management LLC acquired a new stake in Edwards Lifesciences during the second quarter worth about $230,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.